CClinicalTrials.gg
Sign In
TerminatedNCT02880111DMBT1Updated Oct 18, 2022

Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients With Pseudomonas Aeruginosa

An observational study in Malignant Brain Tumor, sponsored by University Hospital, Lille. Terminated at 1 site in France. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2022-10-18.

Sponsored by University Hospital, Lille · Observational

Why this study was terminated
only one patient was included
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
1
Ages
6 Years and older
Sex
All
01

Study summary

Rates of DMBT1 (Glycoprotein like) in Sputum of CF Patients with or without may be different according to their Pseudomonas Aeruginosa chronic colonization status. The aim of this study is to compare rates of DMBT1 (Glycoprotein like) in Sputum of CF patients with or without a Pseudomonas Aeruginosa chronic colonization.

Read the detailed description

Rates of DMBT1 (Deleted in Malignant Brain Tumor 1) will be compared between 2 groups of 30 CF patients : group 1 : with Pseudomonas Aeruginosa chronic colonization and group 2 30 CF patients without Pseudomonas Aeruginosa chronic colonization.

02

Conditions studied

  • Malignant Brain Tumor

Browse trials for

Keywords

  • Malignant Brain Tumor
  • patient sputum
03

In context

Brain Neoplasms

1,959 studies on the registry are indexed under Brain Neoplasms; 515 are open to participants now.

This study's enrollment of 1 is below the median of 100 across 380 observational studies indexed under Brain Neoplasms.

Browse Brain Neoplasms studies →

Lead sponsor

University Hospital, Lille is the lead sponsor of 625 studies on the registry; 141 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

CF Patients with or without Pseudomonas aeruginosa chronic colonization status aged 6 years.

Inclusion criteria

  • CF patient 6 years
  • Availability of sputum
  • Signed Informed consent

Exclusion criteria

Exclusion Criteria:

  • Cardiac insufficiency
  • Anti-inflammatory drugs on going
  • Oral corticosteroid therapy
  • Inhaled corticosteroids during the two weeks before inclusion,
  • Patient awaiting lung transplantation
  • Patient with a past history of heart/lung transplantation
  • Patient with a sputum examination positive for : atypical mycobacteria, Burkholderia cepacia, Stenotrophomonas maltophilia,
  • Patient chronically colonized with multiresistant Pseudomonas aeruginosa
  • Orkambi© or Kalydeco© therapy
  • Change of the CF treatment during the last 4 weeks +/- 2 days before inclusion : corticosteroid, pancreatic extracts, antisecretory drugs...
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
1 participant (actual)
Patient registry
No

Groups and cohorts

  • group 1

    CF patients with Pseudomonas aeruginosa chronic colonization.

  • group 2

    CF patients without a Pseudomonas aeruginosa chronic colonization.

06

What researchers measure

Primary outcomes

  1. measure glycoprotein-like DMBT1 by Elisa

    DMBT1 in mg DMBT1 / mg of total protein measured by BCA (BiCinchoninic acid Assay) present in each sputum

    Time frame: at 1 months

Secondary outcomes

  1. measure MUC5B by Elisa

    MUCB in mg / mg of total protein measured by BCA present in each sputum

    Time frame: at 1 months

07

Study locations

1 site
  • Hôpital Jeanne de Flandre - CHRU de Lille
    Lille, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02880111
Lead sponsor
University Hospital, Lille
Collaborators
Ministry of Health, France
Responsible party
Sponsor
First posted
Aug 26, 2016
Start date
Mar 23, 2016
Primary completion
Mar 2022
Completion
Mar 2022
Last update
Oct 18, 2022

Study contacts

Dominique Turck, MD, PhD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Brain Neoplasms→

Other studies from this sponsor

University Hospital, Lille

Start the discussion